ClinicalTrials.gg
RecruitingNCT05837767Updated Sep 2, 2026

A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue

An interventional study of Palliative radiotherapy in Invasive Ductal Breast Carcinoma, Invasive Ductal Breast Carcinoma Stage IV and Lobular Breast Carcinoma, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by Memorial Sloan Kettering Cancer Center · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2023; still recruiting 3 years 3 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
26
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to find out whether lattice radiation therapy (LRT) is an effective radiation therapy technique when compared to standard stereotactic body radiation therapy (SBRT). The study will also study how the different radiation therapy techniques (LRT and SBRT) affect how many immune cells are able to attack and kill tumor cells (immune infiltration).

02

Conditions studied

  • Invasive Ductal Breast Carcinoma
  • Invasive Ductal Breast Carcinoma Stage IV
  • Lobular Breast Carcinoma
  • Lobular Breast Carcinoma Stage IV
  • Non Small Cell Lung Cancer
  • NSCLC
  • Gastrointestinal Cancer
  • Gastrointestinal Squamous Cell Cancer
  • Gastrointestinal Adenocarcinoma
  • Pancreatic Cancer
  • Bladder Cancer
  • Renal Cell Carcinoma
  • Melanoma
  • Sarcoma
  • Metastatic Solid Tumor

Keywords

  • Invasive Ductal Breast Carcinoma
  • Lobular Breast Carcinoma
  • Non Small Cell Lung Cancer
  • NSCLC
  • Gastrointestinal Cancer
  • Gastrointestinal Squamous Cell Cancer
  • Pancreatic Cancer
  • Bladder Cancer
  • Renal Cell Carcinoma
  • Melanoma
  • Sarcoma
  • Metastatic Solid Tumor
  • extra-cranial disease
  • lattice radiation therapy
  • LRT
  • spatially fractionated radiation therapy
  • SFRT
  • SBRT
  • stereotactic body radiation therapy
  • 22-207
  • Memorial Sloan Kettering Cancer Center
03

In context

Carcinoma, Ductal, Breast

86 studies on the registry are indexed under Carcinoma, Ductal, Breast; 7 are open to participants now.

This study's planned enrollment of 26 is below the median of 92 across 69 interventional studies indexed under Carcinoma, Ductal, Breast.

Browse Carcinoma, Ductal, Breast studies →

Lead sponsor

Memorial Sloan Kettering Cancer Center is the lead sponsor of 1,964 studies on the registry; 327 are open to participants now.

Of its 135 completed or terminated interventional studies of FDA-regulated products, 71 (53%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with confirmed advanced/ solid tumors of the following types: invasive ductal or lobular breast carcinoma (all histological and intrinsic subtypes), non-small cell lung cancer (NSCLC, all subtypes), gastrointestinal squamous cell or adenocarcinomas (including pancreatic cancer), bladder cancer, renal cell carcinoma, melanoma, and soft tissue sarcoma (all subtypes), who require and are being planned for palliative radiation therapy to at least one site of extracranial metastatic disease measuring at least 5 cm in a single axis. If a patient, requires palliative radiotherapy to additional sites, these can be treated with standard of care SBRT per departmental guidelines.
  • Age ≥ 18 years
  • Performance Status of 0 or 1.

Exclusion criteria

Exclusion Criteria:

  • Patients who are pregnant or breastfeeding
  • Prior radiation therapy to the candidate sites under consideration for treatment ("re-irradiation" is disallowed).
  • Medical condition such as uncontrolled infection (including ), uncontrolled diabetes mellitus, or connective tissue diseases (lupus, systemic sclerosis, or other collagen vascular diseases) that, in the opinion of the treating physician, would make this protocol unreasonably hazardous for the patient.
  • Patients with a "currently active" metastatic second .
  • Patients on oral or parental . Physiological doses of steroids are permitted (eg for patients with adrenal insufficiency). If patients are on supraphysiological doses of steroids, these must be discontinued and held during the period of the study.
  • Concomitant anti-neoplastic treatment is not allowed during the days of radiation treatment delivery and should be completed or held for 3 days prior to commencement of protocol treatment and for 3 days following completion of radiotherapy, or with resolution of associated acute toxicities.
  • Unwilling or unable to participate in all required study evaluations and procedures.
  • Unable to understand the purpose and risks of the study and to provide a signed and dated form (ICF) and authorization to use protected health information (in accordance with national and local patient privacy regulations).
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
26 participants (estimated)

Study arms

  • Experimental
    Participants with metastatic solid tumors

    Participants will have metastatic solid tumors and at least two sites of measurable extra-cranial disease

    Radiation: Palliative radiotherapy

Interventions

  • RadiationPalliative radiotherapy

    Palliative radiotherapy (RT) will be performed using external beam ionizing radiation in accordance with standard practice

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR)

    The primary endpoint is ORR in the LRT-treated lesion, as defined by RECIST v.1.1 criteria, at 12 weeks on a standard-of-care response assessment CT or F-18-FDG PET/CT scan after LRT.

    Time frame: 12 weeks from baseline

07

Study locations

7 of 7 sites recruiting
  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
    Basking Ridge, New Jersey 07920, United States
    Recruiting
    • Atif Khan, MD · Contact848-225-6334
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
    Middletown, New Jersey 07748, United States
    Recruiting
    • Atif Khan, MD · Contact848-225-6334
  • Memorial Sloan Kettering Bergen (Limited protocol activities)
    Montvale, New Jersey 07645, United States
    Recruiting
    • Atif Khan, MD · Contact848-225-6334
  • Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities)
    Commack, New York 11725, United States
    Recruiting
    • Atif Khan, MD · Contact848-225-6334
  • Memorial Sloan Kettering Westchester (All Protocol Activities)
    Harrison, New York 10604, United States
    Recruiting
    • Atif Khan, MD · Contact848-225-6334
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)
    New York, New York 10065, United States
    Recruiting
    • Atif Khan, MD · Contact848-225-6334
  • Memorial Sloan Kettering Nassau (Limited protocol activities)
    Rockville Centre, New York 11553, United States
    Recruiting
    • Atif Khan, MD · Contact848-225-6334
08

References and documents

Individual participant data

Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05837767
Responsible party
Sponsor
First posted
May 1, 2023
Start date
Jul 24, 2023
Primary completion
Jul 24, 2027 (estimated)
Completion
Jul 24, 2027 (estimated)
Last update
Sep 2, 2026

Study contacts

Atif Khan, MD
Contact
khana7@mskcc.org
848-225-6334
Christopher Barker, MD
Contact
barkerc@mskcc.org
212-639-8168
Atif Khan, MD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion